Kevin Schwartzman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4001754/publications.pdf

Version: 2024-02-01

87 papers

4,230 citations

126858 33 h-index 63 g-index

87 all docs 87 docs citations

87 times ranked

4890 citing authors

#	Article	IF	CITATIONS
1	Chapter 2: Transmission and pathogenesis of tuberculosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 22-32.	0.2	2
2	Chapter 13: Tuberculosis surveillance and tuberculosis infection testing and treatment in migrants. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 194-204.	0.2	3
3	The association between video-based assessment of intraoperative technical performance and patient outcomes: a systematic review. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 7938-7948.	1.3	15
4	Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Medicine, 2022, 19, e1004032.	3.9	6
5	Social and behavioral risk reduction strategies for tuberculosis prevention in Canadian Inuit communities: a cost-effectiveness analysis. BMC Public Health, 2021, 21, 280.	1.2	3
6	Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting. BMJ Open, 2021, 11, e047514.	0.8	9
7	The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination. American Journal of Epidemiology, 2021, , .	1.6	1
8	The Lobe That Got Away. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
9	Active screening for tuberculosis in high-incidence Inuit communities in Canada: a cost-effectiveness analysis. Cmaj, 2021, 193, E1652-E1659.	0.9	4
10	Triage of Persons With Tuberculosis Symptoms Using Artificial Intelligence–Based Chest Radiograph Interpretation: A Cost-Effectiveness Analysis. Open Forum Infectious Diseases, 2021, 8, ofab567.	0.4	6
11	The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 2020, 24, 115-122.	0.9	13
12	Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical Infectious Diseases, 2020, 73, e3545-e3554.	2.9	19
13	Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. European Respiratory Journal, 2020, 55, 1902048.	3.1	31
14	Mobile phone short message service for adherence support and care of patients with tuberculosis infection: Evidence and opportunity. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 16, 100108.	0.6	22
15	Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. PLoS Medicine, 2019, 16, e1002824.	3.9	27
16	Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 69, 2101-2108.	2.9	26
17	The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities. BMC Medicine, 2019, 17, 26.	2.3	6
18	Improved Disease-free Survival After Prehabilitation for Colorectal Cancer Surgery. Annals of Surgery, 2019, 270, 493-501.	2.1	129

#	Article	IF	CITATIONS
19	Proximate determinants of tuberculosis in Indigenous peoples worldwide: a systematic review. The Lancet Global Health, 2019, 7, e68-e80.	2.9	39
20	Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Annals of the American Thoracic Society, 2018, 15, 570-580.	1.5	43
21	The impact of digital health technologies on tuberculosis treatment: a systematic review. European Respiratory Journal, 2018, 51, 1701596.	3.1	109
22	Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. European Respiratory Journal, 2018, 52, 1801363.	3.1	36
23	Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. European Respiratory Review, 2018, 27, 170102.	3.0	53
24	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. New England Journal of Medicine, 2018, 379, 440-453.	13.9	267
25	Safety and Side Effects of Rifampin versus Isoniazid in Children. New England Journal of Medicine, 2018, 379, 454-463.	13.9	124
26	You pay for what you get: the true cost of tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 969-969.	0.6	1
27	Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC Medicine, 2017, 15, 104.	2.3	19
28	Impact of rapid investigation clinic on timeliness of lung cancer diagnosis and treatment. BMC Pulmonary Medicine, 2017, 17, 178.	0.8	13
29	Maternal sleep-disordered breathing and the risk of delivering small for gestational age infants: a prospective cohort study. Thorax, 2016, 71, 719-725.	2.7	67
30	Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort study. BMC Infectious Diseases, 2016, 16, 679.	1.3	12
31	Xpert®MTB/RIF for the Diagnosis of Tuberculosis in a Remote Arctic Setting: Impact on Cost and Time to Treatment Initiation. PLoS ONE, 2016, 11, e0150119.	1.1	10
32	Latent Tuberculosis in Pregnancy: A Systematic Review. PLoS ONE, 2016, 11, e0154825.	1.1	50
33	Respiratory Medicine and Research at McGill University: A Historical Perspective. Canadian Respiratory Journal, 2015, 22, e4-e7.	0.8	0
34	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clinical Trials, 2015, 16, 100-110.	2.0	22
35	Towards probabilistic decision support in public health practice: Predicting recent transmission of tuberculosis from patient attributes. Journal of Biomedical Informatics, 2015, 53, 237-242.	2.5	9
36	The impact of tuberculosis on health utility: a longitudinal cohort study. Quality of Life Research, 2015, 24, 1337-1349.	1.5	11

3

#	Article	IF	CITATIONS
37	Health-related quality of life and tuberculosis: a longitudinal cohort study. Health and Quality of Life Outcomes, 2015, 13, 65.	1.0	37
38	Potential Cost-Effectiveness of a New Infant Tuberculosis Vaccine in South Africa - Implications for Clinical Trials: A Decision Analysis. PLoS ONE, 2014, 9, e83526.	1.1	10
39	Maternal sleep-disordered breathing and adverse pregnancy outcomes: aÂsystematic review and metaanalysis. American Journal of Obstetrics and Gynecology, 2014, 210, 52.e1-52.e14.	0.7	181
40	Xpert MTB/RIF Testing in a Low Tuberculosis Incidence, High-Resource Setting: Limitations in Accuracy and Clinical Impact. Clinical Infectious Diseases, 2014, 58, 970-976.	2.9	87
41	Accuracy of prospective space–time surveillance in detecting tuberculosis transmission. Spatial and Spatio-temporal Epidemiology, 2014, 8, 47-54.	0.9	5
42	Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. European Respiratory Journal, 2014, 43, 566-581.	3.1	17
43	Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. Journal of Epidemiology and Global Health, 2013, 3, 105.	1.1	14
44	Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. European Respiratory Journal, 2013, 42, 480-494.	3.1	59
45	Development of a Simple Reliable Radiographic Scoring System to Aid the Diagnosis of Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e54235.	1.1	34
46	Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability?. PLoS ONE, 2013, 8, e54748.	1.1	63
47	Hepatitis B Screening and Vaccination Strategies for Newly Arrived Adult Canadian Immigrants and Refugees: A Cost-Effectiveness Analysis. PLoS ONE, 2013, 8, e78548.	1.1	47
48	Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis. Journal of the Neurological Sciences, 2012, 316, 158-163.	0.3	33
49	TB Screening in Canadian Health Care Workers Using Interferon-Gamma Release Assays. PLoS ONE, 2012, 7, e43014.	1.1	30
50	Health Care Utilization by Preterm Infants with Respiratory Complications in Quebec. Canadian Respiratory Journal, 2012, 19, 255-260.	0.8	25
51	Developing a Tuberculosis Transmission Model That Accounts for Changes in Population Health. Medical Decision Making, 2011, 31, 53-68.	1.2	10
52	Tuberculosis and homelessness in Montreal: a retrospective cohort study. BMC Public Health, 2011, 11, 833.	1.2	22
53	Adverse events associated with treatment of latent tuberculosis in the general population. Cmaj, 2011, 183, E173-E179.	0.9	51
54	Residential address errors in public health surveillance data: A description and analysis of the impact on geocoding. Spatial and Spatio-temporal Epidemiology, 2010, 1, 163-168.	0.9	23

#	Article	IF	CITATIONS
55	Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax, 2010, 65, 582-587.	2.7	47
56	Earthquake in Haiti: is the Latin American and Caribbean region's highest tuberculosis rate destined to become higher?. Expert Review of Respiratory Medicine, 2010, 4, 417-419.	1.0	7
57	Tuberculosis in Town: Mobility of Patients in Montreal, 1925–1950. Histoire Sociale, 2009, 42, 69-106.	0.0	2
58	Major <i>Mycobacterium tuberculosis</i> Lineages Associate with Patient Country of Origin. Journal of Clinical Microbiology, 2009, 47, 1119-1128.	1.8	154
59	Tuberculosis and the city. Health and Place, 2009, 15, 807-813.	1.5	6
60	Knowledge and Perceptions of Tuberculosis Among a Sample of Urban Aboriginal People. Journal of Community Health, 2008, 33, 192-198.	1.9	19
61	Bayesian modelling of tuberculosis clustering from DNA fingerprint data. Statistics in Medicine, 2008, 27, 140-156.	0.8	16
62	Tuberculosis screening of travelers to higher-incidence countries: A cost-effectiveness analysis. BMC Public Health, 2008, 8, 201.	1.2	15
63	Collapse and Expand: Architecture and Tuberculosis Therapy in Montreal, 1909, 1933, 1954. Technology and Culture, 2008, 49, 908-942.	0.0	19
64	Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection. Annals of Internal Medicine, 2008, 149, 689.	2.0	180
65	T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data. PLoS ONE, 2008, 3, e1850.	1.1	89
66	Strategies to Prevent Varicella among Newly Arrived Adult Immigrants and Refugees: A Cost-Effectiveness Analysis. Clinical Infectious Diseases, 2007, 44, 1040-1048.	2.9	26
67	Susceptibility to Measles, Mumps, and Rubella in Newly Arrived Adult Immigrants and Refugees. Annals of Internal Medicine, 2007, 146, 20.	2.0	47
68	Prevalence of Abnormal Radiological Findings in Health Care Workers with Latent Tuberculosis Infection and Correlations with T Cell Immune Response. PLoS ONE, 2007, 2, e805.	1.1	36
69	Contact Investigation and Genotyping to Identify Tuberculosis Transmission to Children. Pediatric Infectious Disease Journal, 2006, 25, 1037-1043.	1.1	25
70	Dwellings, crowding, and tuberculosis in Montreal. Social Science and Medicine, 2006, 63, 501-511.	1.8	49
71	Economic Benefits of Self-Management Education in COPD. Chest, 2006, 130, 1704-1711.	0.4	171
72	Sensitivities and Specificities of Spoligotyping and Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeat Typing Methods for Studying Molecular Epidemiology of Tuberculosis. Journal of Clinical Microbiology, 2005, 43, 89-94.	1.8	53

#	Article	IF	Citations
73	Domestic Returns from Investment in the Control of Tuberculosis in Other Countries. New England Journal of Medicine, 2005, 353, 1008-1020.	13.9	136
74	Extraction of Mycobacterium tuberculosis DNA: a Question of Containment. Journal of Clinical Microbiology, 2005, 43, 2996-2997.	1.8	165
75	Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 445-449.	2.5	155
76	Recurrent Tuberculosis in the United States and Canada. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1360-1366.	2. 5	116
77	Diversity of Mycobacterium tuberculosis Isolates in an Immigrant Population: Evidence against a Founder Effect. American Journal of Epidemiology, 2004, 159, 507-513.	1.6	13
78	Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. Quality of Life Research, 2004, 13, 653-665.	1.5	54
79	Widespread Pyrazinamide-Resistant Mycobacterium tuberculosis Family in a Low-Incidence Setting. Journal of Clinical Microbiology, 2003, 41, 2878-2883.	1.8	34
80	Teaching Time for Metered-Dose Inhalers in the Emergency Setting. Chest, 2002, 122, 498-504.	0.4	13
81	Yield of Laboratory Testing to Identify Secondary Contributors to Osteoporosis in Otherwise Healthy Women. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4431-4437.	1.8	281
82	Measurement of Health Preferences among Patients with Tuberculous Infection and Disease. Medical Decision Making, 2002, 22, 102-114.	1.2	28
83	Latent tuberculosis infection: old problem, new priorities. Cmaj, 2002, 166, 759-61.	0.9	3
84	Strategies Incorporating Spiral CT for the Diagnosis of Acute Pulmonary Embolism. Chest, 2001, 119, 1791-1800.	0.4	63
85	Comparison of Cost-Effectiveness of Tuberculosis Screening of Close Contacts and Foreign-Born Populations. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2079-2086.	2.5	122
86	Tuberculosis Screening of Immigrants to Low-Prevalence Countries. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 780-789.	2.5	100
87	Local Determinants of Response to Endobronchial High-Dose Rate Brachytherapy in Bronchogenic Carcinoma. Chest, 1997, 112, 946-953.	0.4	31